An antigen-less pro-vaccine for treating autoimmunity.

Area of Science:

• Immunology
• Pharmacology
• Biotechnology

Background:

• Autoimmune diseases pose a significant therapeutic challenge.
• Current treatments often require specific antigen identification and can have systemic side effects.
• There is a need for innovative immunotherapies that can induce tolerance without requiring exogenous antigens.

Purpose of the Study:

• To design and evaluate a novel antigen-less pro-vaccine, designated 8206, for the treatment of autoimmune diseases.
• To investigate the mechanism of action of 8206 in inducing antigen-specific regulatory T cell expansion.
• To assess the efficacy of 8206 in a preclinical model of atherosclerosis.

Main Methods:

• The pro-vaccine 8206 was formulated using dexamethasone, rapamycin, and R848 at an 8:20:6 mass ratio.
• 8206 was administered systemically to induce an in situ vaccine with endogenous autoantigens.
• Antigen-specific regulatory T cell expansion and disease progression were assessed in a mouse model of atherosclerosis targeting ApoB, HSP60, and HMGB1.

Main Results:

• 8206 demonstrated the ability to act as a complete tolerogenic adjuvant, forming an active vaccine in situ.
• The pro-vaccine successfully expanded antigen-specific Treg cells in affected tissues, suppressing autoimmunity.
• In a mouse model of atherosclerosis, 8206 effectively targeted pathogenic autoantigens and inhibited disease progression.

Conclusions:

• 8206 represents the first designed antigen-less pro-vaccine for autoimmune disease treatment.
• This approach eliminates the need for exogenous immunogens, suggesting potential as a universal immunotherapy.
• The findings have broad implications for the development of novel vaccines and immunotherapies for autoimmune conditions.